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demonstrating that imatinib mesylate can prevent human T-cell responses to CD3/CD28 or PHA stimulation. The blocking mechanism of imatinib shown by the authors is direct on T cells, does not cause induction of apoptosis and is reversible. Therefore, the authors suggest that the use of imatinib after allogeneic stem cell transplantation may result in a reduced graft-versus-leukemia effect. Similar in vitro results were also reported in another recent study. 2 Indeed, these experimental findings might explain a clinical case that we observed, which raises the question if patients who undergo an allogeneic stem cell transplantation, after failing to achieve a cytogenetic response on imatinib, may accelerate their relapse upon restarting imatinib post-transplant. Our case relates to a 49-year-old patient with a t(1;9;22) chronic myeloid leukemia at day 30 after transplant. At 4 months post-transplant, because of chimerism o90%, detectable disease at molecular level, 4 and absence of GVHD, the immunosuppression was stopped. Figure 1 illustrates the relationship between chimerism levels and molecular minimal residual disease, tested by RQ-PCR, at different time-points. At 8 months after transplant, the chimerism was still 84%. Therefore, imatinib was restarted with the aim of obtaining some effect on the tumor burden 5 to help possibly the donor cells to achieve a full chimerism and a complete molecular remission. Three months later, instead, imatinib was stopped because the chimerism had progressively slightly decreased and molecular p210 levels were unchanged. Moreover, 1 month later a cytogenetic relapse in 30% of blood cells, a 12% molecular minimal residual disease, and a drop of 
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Figure 1
Correlation between donor cell chimerism (triangle symbols, refer to linear scale on the left) and minimal residual disease (square symbols, refer to logarithmic scale on the right) in a CML patient after allogeneic peripheral blood stem cell transplantation. Sequential therapeutical procedures, including withdrawal of tacrolimus (STOP FK 506), imatinib mesylate therapy (Gleevec 400 mg) and donor leukocyte infusion (DLI), as well as development of acute graft-versus-host disease (GVHD), are also indicated. chimerism to 58% were documented. The patient received an initial donor lymphocyte infusion (with 10 8 T-cells/kg), and in 5 weeks improved both donor cell chimerism and bcr-abl molecular levels in the absence of any sign of GVHD. Upon a second donor leukocyte infusion (DLI), the patient developed acute GVHD grade II and in two consecutive tests his chimerism has been 100% donor and is in complete molecular remission. In this case, the patient was resistant to imatinib post-transplant, but it seems that treatment with imatinib post-transplant preceded a drop in donor cell chimerism as well as a cytogenetic relapse, which was successfully treated with DLI. Since, instead, it has been reported a beneficial effect of the association of imatinib and DLI, 6 we hypothesize that in patients partially responding/resistant to imatinib pretransplant, a possible T-cell suppressive effect of imatinib post-transplant could result in a reduced graft-versus leukemia, possibly facilitating a progression of the disease. 
